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Background: Angiogenesis has been extensively studied in acute myeloid leukemia (AML). Lactate dehydrogenase (LDH),
a common biochemical marker for tumor burden and anaerobic glycolysis, is a poor prognostic factor for AML. Regulated by
hypoxia-induced factor, both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are responsive
to cancer-related angiogenesis. To study the roles of serum LDH, VEGF and bFGF in AML angiogenesis, we investigated
bone marrow vascularity in untreated AML patients, and analyzed its relationship to serum LDH, VEGF and bFGF levels.
Methods: Eighteen (11 males, 7 females; mean age, 57.7 years) de novo, untreated AML patients were enrolled. Bone
marrow vascularity was evaluated by staining bone marrow core biopsy tissue with endothelial cell marker CD31 or
CD34. Serum LDH was determined with the Wroblewski-La Due method. Serum VEGF and bFGF were determined with
enzyme-linked immunoassay. The relationship of LDH, VEGF and bFGF level to bone marrow vessel numbers was exam-
ined by linear regression.
Results: Log LDH significantly correlated to AML bone marrow vascularity (r = 0.61; p = 0.007). VEGF and bFGF concen-
trations did not correlate with AML angiogenesis.
Conclusion: These results suggest that serum LDH, but not VEGF and bFGF concentrations, can be used as a simple
parameter for predicting vessel formation in AML bone marrow. [J Chin Med Assoc 2006;69(11):534–537]
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Introduction
Angiogenesis is a complex, multistep process by which
new microvessels are formed from preexisting vascu-
lature.1 Hypoxia is the factor most responsible for this
process.2 Increased anaerobic glycolysis due to elevated
tumor cell proliferation and metabolism is one of the
most important physiologic responses to hypoxia. When
tissue undergoes anaerobic glycolysis, lactate dehy-
drogenase (LDH) increases to accelerate conversion
of pyruvate to lactate, yielding energy.3 At the molec-
ular level, hypoxia induces expression of vascular
endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) for angiogenesis.2 Increased
angiogenesis has been observed in acute myeloid
leukemia (AML) patients.4 Simple parameters for pre-
diction of angiogenetic ability in AML remain unclear.
We investigated the association of peripheral blood
serum LDH, VEGF and bFGF with bone marrow
vascularity in AML patients.
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Methods
Study subjects
Study subjects were 18 untreated, de novo AML patients
(11 males, 7 females; mean age, 57.7 ± 18.2 years). The
diagnosis of AML was determined according to criteria
proposed by the French-American-British Cooperative
Group in 1984.5 Patient enrollment was voluntary and
with informed consent. This project was approved by
the institutional review board of Taichung Veterans
General Hospital (No. 940103/453).
Bone marrow vessel counting
After staining bone marrow core biopsy tissue with
endothelial cell marker CD31 (1:1,600; Dako Inc.,
Carpinteria, CA, USA) or CD34 (1:500; Vector
Laboratories Inc., Burlingame, CA, USA) (Figure 1),
2 of the authors separately assessed vessel number in
each bone marrow biopsy slide with light microscopy
(400×) in 5 areas containing the highest numbers of
vessels, as described by Padro et al.4
LDH, VEGF and bFGF assays
All assays were determined in duplicate; the mean value
was used in statistical analysis. LDH in blood sera was
determined with the Wroblewski-La Due method 
kit (Wako Ltd., Osaka, Japan). VEGF and bFGF in
blood sera were determined with quantitative sand-
wich enzyme human VEGF and bFGF immunoassay
kits (R&D Systems Inc., Minneapolis, MN, USA).
LDH levels are presented in IU/L, and VEGF and
bFGF concentrations in pg/mL. The minimum detec-
tion limits for VEGF and bFGF were 9 pg/mL and
3 pg/mL, respectively.
Statistical analysis
The relationship of LDH, VEGF and bFGF concen-
trations to bone marrow vessel numbers and corre-
lation among LDH, VEGF and bFGF were examined
by linear regression. LDH was log transformed to
improve similarity to normal distribution. Statistical
analysis was performed using SPSS version 11.5 (SPSS
Inc., Chicago, IL, USA). Significance was set at p <0.05.
Results
Patients’ basic data and original experimental results,
including bone marrow vascularity, LDH level,
VEGF and bFGF concentrations, are shown in 
Table 1. Vessel numbers in AML patients’ bone mar-
row tissue were positively correlated to log peripheral
blood serum LDH (Pearson’s correlation coefficient,
r = 0.61; p = 0.007) (Figure 2). VEGF data were not
available for 2 patients due to insufficient specimens.
Peripheral blood serum bFGF could not be detected
in most of the patients. Bone marrow vascularity did
not correlate to either peripheral blood serum VEGF
or bFGF concentrations (VEGF: r = 0.44, p = 0.86;
bFGF: r = 0.22, p = 0.39). There were no correlations
among LDH, VEGF and bFGF concentrations.
Discussion
Angiogenesis has been extensively studied in AML,6
but simple parameters for predicting degree of AML
angiogenesis are still absent. Our study demonstrated
that serum LDH level is positively correlated to bone
marrow vascularity in AML.
High LDH is a poor prognostic factor for several
malignancies, including AML.7 Some possible mecha-
nisms have been proposed. First, acidification of the
extracellular water space by lactate and the subsequent
activation of tumor invasion may be a rational expla-
nation.8 Second, low pH microenvironment may
increase cancer cell resistance to hypoxia-induced
apoptosis by protecting mitochondria from oxidative
stress.9,10 And third, overexpression of LDH, espe-
cially LDH5, reflects an upregulated hypoxia-induced
factor pathway, which regulates glycolysis, angiogenesis,
resistance to apoptosis, and even cancer metastasis.11–13
Due to difficulty in counting leukemic tumor bur-
den by tumor size or number of tumor cells, LDH is
viewed as a simple biochemical marker for leukemic
tumor burden prediction. Furthermore, Vidriales et al14
showed that serum LDH level was proportional to
leukemic cells in synthetic phase. Also, bone marrow
Figure 1. Immunohistochemical stain of bone marrow biopsy with
CD31 showing brown-colored endothelial cells with vessel struc-
ture (arrows) (immunohistochemical stain with CD31, 400×).
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microenvironment plays an important role in elevated
LDH in AML. Compared to other solid malignan-
cies, AML obviously has a higher cell proliferation
rate. Under rapid proliferation and immaturity of
tumor cells, LDH is released due to multiple cytokine
activity and cell membrane damage.15 The correlation
between serum LDH and vascularity in AML bone
marrow may reflect not only the degree of microenvi-
ronmental hypoxia, but also the degree of marrow
involvement with leukemic cells, the aggressiveness of
the leukemia, or the involvement of various cytokines.
As previously mentioned, LDH reflects an upreg-
ulated hypoxia-induced factor pathway. VEGF and
bFGF, positively regulated by hypoxia-induced factor,
were also surveyed in this study. The roles of VEGF
and bFGF in AML angiogenesis remain controversial.
The importance of both VEGF and bFGF in AML
angiogenesis was reported,16,17 but it has also been
proposed that both VEGF and bFGF concentrations
in AML patients are similar to those in healthy peo-
ple.17,18 VEGF receptors, rather than VEGF itself, have
prognostic value.18 A study by Bieker et al16 demon-
strated that degree of bFGF expression in AML did 
not correlate with microvessel density. Our study con-
firmed their results, and further demonstrated the lack
of correlation between serum VEGF level and AML
bone marrow vascularity. Serum VEGF and bFGF were
not good molecular markers of angiogenesis in AML.
VEGF and bFGF are currently known to be
growth factors for hematopoietic cells, and not just
angiogenic factors.19,20 The local effects of VEGF and
bFGF on leukemic cell proliferation or angiogenesis
may not be reflected in their peripheral blood con-
centrations. Further studies are required to answer
this question.
We found a positive correlation between serum
LDH level and bone marrow vascularity in AML
patients, but no correlation of serum VEGF and bFGF
levels with AML angiogenesis. These results suggest that
serum LDH, but not VEGF and bFGF concentrations,
can be used as a simple parameter in the evaluation of
the angiogenic ability of AML. Anti-angiogenesis
therapy is now rapidly developing in cancer treatment.
Our findings may establish a simple indicator and
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Figure 2. The number of vessels in acute myeloid leukemia bone
marrow tissue is positively correlated to the log of blood serum
lactate dehydrogenase activity (Log LDH) (p = 0.007).
Table 1. Patients’ basic data and original experimental results
Patient FAB classification Sex Age (yr) Vessel no. LDH (IU/L) VEGF (pg/mL) bFGF (pg/mL)
1 M3 M 29 37 617 84.8 < 3
2 M0 F 36 19 269 80.2 < 3
3 M2 F 50 9 373 38.7 < 3
4 M2 M 66 18 172 127.3 < 3
5 M2 M 69 21 403 134.6 < 3
6 M2 M 70 28 832 101.1 < 3
7 M2 M 29 24 302 91.6 4.2
8 M3 F 49 38 429 150.4 < 3
9 M4 F 76 57 352 N/A < 3
10 M2 M 74 18 323 206.6 < 3
11 M3 M 38 28 1,028 91.3 < 3
12 M1 F 49 37 260 158.8 4.6
13 M4 M 75 20 474 158.1 3.5
14 M3 M 42 51 1,689 988.2 6.0
15 M2 F 82 30 929 N/A < 3
16 M4 F 58 55 4,621 214.1 < 3
17 M4 M 61 25 321 46.4 < 3
18 M2 M 86 19 363 538.2 < 3
FAB = French-American-British; LDH = lactate dehydrogenase; VEGF = vascular endothelial growth factor; bFGF = basic fibroblast growth factor; N/A = not available.
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rationale that AML patients with high serum LDH level
may be candidates for anti-angiogenesis treatment.
Acknowledgments 
We thank Taichung Veterans General Hospital for
supporting the research (TCVGH-943701A) and 
statistical consultation.
References
1. Carmeliet P. Angiogenesis in health and disease. Nat Med
2003;9:653–60.
2. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia:
role of the HIF system. Nat Med 2003;9:677–84.
3. Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of
tumor malignancy. Semin Radiat Oncol 2004;14:267–74.
4. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J,
Buchner T, et al. Increased angiogenesis in the bone marrow of
patients with acute myeloid leukemia. Blood 2000;95:2637–44.
5. Bernard P, Reiffers J, Lacombe F, Dachary D, Boisseau MR,
Broustet A. A stage classification for prognosis in adult acute
myelogenous leukaemia based upon patients’ age, bone mar-
row karyotype and clinical features. Scand J Haematol 1984;
32:429–40.
6. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased
angiogenesis in patients with acute myeloid leukemia. Blood
2000;95:309–13.
7. Krykowski E, Polkowska-Kulesza E, Robak T, Matusewicz W,
Urbanska-Rys H, Holub A. Analysis of prognostic factors in
acute leukemias in adults. Haematol Blood Transfus 1987;30:
369–72.
8. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes
and consequences of tumour acidity and implications for treat-
ment. Mol Med Today 2000;6:15–9.
9. Bronk SF, Gores GJ. Acidosis protects against lethal oxidative
injury of liver sinusoidal endothelial cells. Hepatology 1991;14:
150–7.
10. Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T. Role for
mitochondrial oxidants as regulators of cellular metabolism.
Mol Cell Biol 2000;20:7311–8.
11. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate
dehydrogenase A: interaction between hypoxia-inducible factor
1 and cAMP response elements. J Biol Chem 1995;270:21021–7.
12. Koukourakis MI, Giatromanolaki A, Simopoulos C,
Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5)
relates to up-regulated hypoxia-inducible factor pathway and
metastasis in colorectal cancer. Clin Exp Metastas 2005;22:
25–30.
13. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet
JP, Maire P, Giallongo A. Hypoxia response elements in the
aldolase A, enolase 1, and lactate dehydrogenase A gene pro-
moters contain essential binding sites for hypoxia-inducible
factor 1. J Biol Chem 1996;271:32529–37.
14. Vidriales MB, Orfao A, Lopez-Berges MC, Gonzalez M, Lopez-
Macedo A, Ciudad J, Lopez A, et al. Prognostic value of 
S-phase cells in AML patients. Br J Haematol 1995;89:342–8.
15. Jurisic V, Kraguljac N, Konjevic G, Spuzic I. TNF-alpha
induced changes in cell membrane antigen expression on 
K-562 cells associated with increased lactate dehydrogenase
(LDH) release. Neoplasma 2005;52:25–31.
16. Bieker R, Padro T, Kramer J, Steins M, Kessler T, Retzlaff S,
Herrera F, et al. Overexpression of basic fibroblast growth 
factor and autocrine stimulation in acute myeloid leukemia.
Cancer Res 2003;63:7241–6.
17. Litwin C, Leong KG, Zapf R, Sutherland H, Naiman SC,
Karsan A. Role of the microenvironment in promoting angiogen-
esis in acute myeloid leukemia. Am J Hematol 2002;70:22–30.
18. Gwang Kim J, Kyun Sohn S, Hwan Kim D, Ho Baek J, Young
Lee N, Soo Suh J, Chae SC, et al. Clinical implications of
angiogenic factors in patients with acute or chronic leukemia:
Hepatocyte growth factor levels have prognostic impact, espe-
cially in patients with acute myeloid leukemia. Leuk Lymphoma
2005;46:885–91.
19. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N,
Stockschlader M, Hossfeld DK. Vascular endothelial growth
factor, a possible paracrine growth factor in human acute
myeloid leukemia. Blood 1997;89:1870–5.
20. Kashiwakura I, Takahashi TA. Fibroblast growth factor and ex vivo
expansion of hematopoietic progenitor cells. Leuk Lymphoma
2005;46:329–33.
